Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin E Lee

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Journal of Thoracic and Cardiovascular Surgery|August 16, 2011
Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett's esophagus: a single-center, phase II clinical trialRobert J Korst, Sobeida Santana-Joseph, John R Rutledge, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2012
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagusRobert J Korst, Sobeida Santana-Joseph, John R Rutledge, et al.
The Journal of Biological Chemistry|October 2, 2008
SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylationAlexander Y Kim, Claire C Bommeljé, Benjamin E Lee, et al.
The Lancet. Oncology|May 20, 2021
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trialNasser K Altorki, Timothy E McGraw, Alain C Borczuk, et al.
Nature Communications|January 3, 2024
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Nature Communications|December 19, 2023
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Journal of Thoracic and Cardiovascular Surgery|August 16, 2011
Effect of hiatal hernia size and columnar segment length on the success of radiofrequency ablation for Barrett's esophagus: a single-center, phase II clinical trialRobert J Korst, Sobeida Santana-Joseph, John R Rutledge, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 11, 2012
Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagusRobert J Korst, Sobeida Santana-Joseph, John R Rutledge, et al.
The Journal of Biological Chemistry|October 2, 2008
SCCRO (DCUN1D1) is an essential component of the E3 complex for neddylationAlexander Y Kim, Claire C Bommeljé, Benjamin E Lee, et al.
The Lancet. Oncology|May 20, 2021
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trialNasser K Altorki, Timothy E McGraw, Alain C Borczuk, et al.
Nature Communications|January 3, 2024
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Nature Communications|December 19, 2023
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trialNasser K Altorki, Zachary H Walsh, Johannes C Melms, et al.
Pageof 3